ArticleAfrican health sciences2024
The impact of COVID-19 pandemic in tuberculosis diagnosis in sub-Saharan Africa: data from DREAM program in Mozambique.
Article in African health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: TB is a global emergency, COVID-19 reversed the trend in TB mortality reduction to 2017 levels. Mozambique is one of the highest-burden countries with 368 new cases per 100.000 population in 2020. Objectives: This analysis aims to evaluate a TB diagnostic service in two Mozambican cities before and during the COVID-19 pandemic. Methods: We reviewed routine activity data from two laboratories in Mozambique (Maputo and Beira) in the period 01/2018-08/2022. GeneXpert test was prescribed based on clinical suspicion. Data about the number of tests, results, and rifampicin resistance were collected. Results: In the period 3,071 tests were conducted: 391 positive, and 32 rifampicin resistant. The number of positive samples was higher in Beira (20.2% vs 5%, OR 4[3.1-5.2]).In Maputo, we observed a higher percentage of rifampicin-resistant samples (13.2%vs7%, OR 0.5[0.2-1.1]), but the overall prevalence of rifampicin resistance was higher in Beira (14.1‰vs6.6‰, OR 2.1[1.0-4.5]).In 2020 and the first semester of 2021 a reduction in activity was observed, but positivity rates remained stable, with a slight increment starting in 2020. Conclusions: Our data confirm the impact of the COVID-19 pandemic on TB diagnostic services but also highlight possible benefits in terms of diagnostic appropriateness in clinical centers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.